CO6190528A2 - Inhibidores de la actividad de la akt - Google Patents

Inhibidores de la actividad de la akt

Info

Publication number
CO6190528A2
CO6190528A2 CO09054952A CO09054952A CO6190528A2 CO 6190528 A2 CO6190528 A2 CO 6190528A2 CO 09054952 A CO09054952 A CO 09054952A CO 09054952 A CO09054952 A CO 09054952A CO 6190528 A2 CO6190528 A2 CO 6190528A2
Authority
CO
Colombia
Prior art keywords
aob
alkyl
cycloalkyl
heterocyclyl
alkynyl
Prior art date
Application number
CO09054952A
Other languages
English (en)
Inventor
Michael Kelly Iii
Mark E Layton
Philip E Sanderson
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of CO6190528A2 publication Critical patent/CO6190528A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)

Abstract

1.- Un compuesto de acuerdo con la Fórmula C:en la que: a es 0 ó1; b es 0 ó 1; m es 0, 1 ó 2; p es 0, 1 ó 2; R2 se selecciona independientemente entre: alquilo (C1-C6), alcoxi (C1-C6); CO2H, halo, OH y NH2; El anillo Y es cicloalquilo (C4-C7); R1 se selecciona entre: H, oxo, (C=O)aObalquilo (C1-C10), (C=O)aOb-arilo, (C=O)aObalquenilo (C2-C10), (C=O)aOb alquinilo (C2-C10), CO2H, halo, OH, Obperfluoroalquilo (C1-C6), (C=O)aNR7R8, CN, (C=O)aOb cicloalquilo (C3-C8), S(O)mNR7R8, SH, S(O)m-alquilo (C1-C10) y (C=O)aOb-heterociclilo, dicho alquilo, arilo, alquenilo, alquinilo, cicloalquilo, y heterociclilo está opcionalmente sustituido con uno o más sustituyentes seleccionados entre R6; R6 es: (C=O)aOb alquilo C1-C10, (C=O)aObarilo, alquenilo C2-C10, alquinilo C2-C10, (C=O)aOb heterociclilo, CO2H, halo, CN, OH, Ob perfluoroalquilo C1-C6, Oa(C=O)bNR7R8, oxo, CHO, (N=O)R7R8, S(O)mNR7R8, SH, S(O)m-alquilo (C1-C10) o (C=O)aOb cicloalquilo C3-C8, dicho alquilo, arilo, alquenilo, alquinilo, heterociclilo, y cicloalquilo opcionalmente sustituido con uno o más sustituyentes seleccionados entre R6a; R6a se selecciona entre: (C=O)aOb alquilo (C1-C10), Oa perfluoroalquilo (C1-C3), alquileno (C0-C6) -S(O)mRa, SH, oxo, OH, halo, CN, alquenilo (C2-C10), alquinilo (C2-C10), cicloalquilo (C3-C6), alquileno (C0-C6)-arilo, alquileno (C0-C6)-heterociclilo, alquilen (C0-C6)-N(Rb)2, C(O)Ra, alquilen (C0-C6) -CO2Ra, C(O)H, y alquilen (C0-C6) -CO2H, dicho alquilo, alquenilo, alquinilo, cicloalquilo, arilo, y heterociclilo está opcionalmente sustituido con hasta tres sustituyentes seleccionados entre Rb, OH, alcoxi (C1-C6), halógeno, CO2H, CN, Oa(C=O)b alquilo (C1-C6), oxo, y N(Rb)2; R7 y R8 se seleccionan independientemente entre: H, (C=O)aOb alquilo (C1-C10), (C=O)aOb cicloalquilo (C3-C8), (C=O)aOb-arilo, (CO)aOb-heterociclilo, alquenilo (C2-C10), alquinilo (C2-C10), SH, SO2Ra, y (C=O)aNRb2, dicho alquilo, cicloalquilo, arilo, heterociclilo, alquenilo, y alquinilo está opcionalmente sustituido con uno o más sustituyentes seleccionados entre R6a, o R7 y R8 se pueden tomar juntos con el nitrógeno al que están unidos para formar a heterociclo monocíclico o bicíclico con 3 - 7 miembros en cada anillo conteniendo opcionalmente, además del nitrógeno, uno o dos heteroátomos adicionales seleccionados entre N, O y S, ...
CO09054952A 2006-12-06 2009-05-28 Inhibidores de la actividad de la akt CO6190528A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87319806P 2006-12-06 2006-12-06
US88066107P 2007-01-16 2007-01-16
US96787207P 2007-09-06 2007-09-06

Publications (1)

Publication Number Publication Date
CO6190528A2 true CO6190528A2 (es) 2010-08-19

Family

ID=39492823

Family Applications (1)

Application Number Title Priority Date Filing Date
CO09054952A CO6190528A2 (es) 2006-12-06 2009-05-28 Inhibidores de la actividad de la akt

Country Status (30)

Country Link
US (3) US7576209B2 (es)
EP (1) EP2104669B1 (es)
JP (2) JP4431636B1 (es)
KR (1) KR101110598B1 (es)
CN (1) CN101600706B (es)
AR (1) AR064010A1 (es)
AU (1) AU2007328286B2 (es)
BR (1) BRPI0719580A2 (es)
CA (1) CA2670760C (es)
CL (1) CL2007003495A1 (es)
CO (1) CO6190528A2 (es)
CR (1) CR10851A (es)
EA (1) EA016195B1 (es)
EC (1) ECSP099376A (es)
ES (1) ES2527567T3 (es)
GE (1) GEP20125469B (es)
GT (1) GT200900146A (es)
HK (1) HK1137758A1 (es)
HN (1) HN2009001112A (es)
IL (2) IL198826A (es)
MA (1) MA31027B1 (es)
MX (1) MX2009006052A (es)
NI (1) NI200900106A (es)
NO (1) NO20092569L (es)
NZ (2) NZ577470A (es)
PE (1) PE20081341A1 (es)
SV (1) SV2009003283A (es)
TN (1) TN2009000224A1 (es)
TW (1) TWI386410B (es)
WO (2) WO2008070041A2 (es)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2409168T3 (es) * 2005-06-10 2013-06-25 Merck Sharp & Dohme Corp. Inhibidores de la actividad Akt
AR064010A1 (es) * 2006-12-06 2009-03-04 Merck & Co Inc Inhibidores de la actividad de la akt
CA2670767A1 (en) * 2006-12-06 2008-06-12 Merck & Co., Inc. Inhibitors of akt activity
US20100048913A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
WO2009148916A1 (en) * 2008-06-03 2009-12-10 Merck & Co., Inc. Inhibitors of akt activity
JP2011522047A (ja) * 2008-06-03 2011-07-28 メルク・シャープ・エンド・ドーム・コーポレイション Ａｋｔ活性の阻害剤
CA2729412A1 (en) 2008-07-04 2010-01-07 Banyu Pharmaceutical Co., Ltd. Novel spirochromanone carboxylic acids
CA2733533C (en) * 2008-08-25 2013-12-17 Irm Llc Hedgehog pathway modulators
DE102008043724A1 (de) * 2008-11-13 2010-05-20 Biotronik Vi Patent Ag Erhöhung der Effizienz pharmazeutische Wirkstoffe-freisetzender Medizinprodukte durch Kombination mit einem Inhibitor des Transportproteins P-Glycoprotein
AU2010208480A1 (en) * 2009-02-02 2011-07-28 Msd K.K. Inhibitors of Akt activity
EP2393827B1 (en) 2009-02-05 2015-10-07 Tokai Pharmaceuticals, Inc. Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens
EP2403339B1 (en) * 2009-03-06 2017-01-18 Merck Sharp & Dohme Corp. Combination cancer therapy with an akt inhibitor and other anticancer agents
WO2010104705A1 (en) 2009-03-12 2010-09-16 Merck Sharp & Dohme Corp. Inhibitors of akt activity
US8691825B2 (en) 2009-04-01 2014-04-08 Merck Sharp & Dohme Corp. Inhibitors of AKT activity
JP5567136B2 (ja) 2009-09-08 2014-08-06 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ４−置換ピリジン−３−イル−カルボキサミド化合物及び使用方法
US8546376B2 (en) 2009-09-18 2013-10-01 Almac Discovery Limited Pharmaceutical compounds
GB0919380D0 (en) 2009-11-04 2009-12-23 Almac Discovery Ltd Pharmaceutical compouds
GB0922589D0 (en) 2009-12-23 2010-02-10 Almac Discovery Ltd Pharmaceutical compounds
WO2011130921A1 (en) * 2010-04-23 2011-10-27 Merck Sharp & Dohme Corp. Inhibitors of akt activity
JP2013526578A (ja) 2010-05-21 2013-06-24 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 組合せ
WO2012007345A2 (en) 2010-07-12 2012-01-19 Bayer Pharma Aktiengesellschaft Substituted imidazo[1,2-a]pyrimidines and -pyridines
JP2013530250A (ja) 2010-07-13 2013-07-25 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 二環式ピリミジン化合物
US8987273B2 (en) 2010-07-28 2015-03-24 Bayer Intellectual Property Gmbh Substituted imidazo[1,2-B]pyridazines
CA2821777A1 (en) * 2010-12-16 2012-06-21 Bayer Intellectual Property Gmbh Substituted pyrimido[1,2-b]indazoles and their use as modulators of the pi3k/akt pathway
KR20140053836A (ko) * 2011-01-11 2014-05-08 글락소스미스클라인 엘엘씨 조합물
SG193327A1 (en) 2011-04-06 2013-10-30 Taiho Pharmaceutical Co Ltd Novel imidazo-oxazine compound or salt thereof
EA024890B1 (ru) * 2011-04-07 2016-10-31 Байер Интеллектчуал Проперти Гмбх Имидазопиридазины в качестве ингибиторов akt киназы
WO2012177852A1 (en) * 2011-06-24 2012-12-27 Arqule, Inc Substituted imidazopyridinyl compounds
ES2579855T3 (es) 2011-06-24 2016-08-17 Arqule, Inc. Compuestos de imidazopiridinil-aminopiridina sustituidos
US9408885B2 (en) 2011-12-01 2016-08-09 Vib Vzw Combinations of therapeutic agents for treating melanoma
JP6106694B2 (ja) 2012-01-10 2017-04-05 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ Ａｋｔキナーゼ阻害剤としての置換ピラゾロピリミジン類
US9260435B2 (en) 2012-01-10 2016-02-16 Bayer Pharma Aktiengesellschaft Substituted imidazopyrazines as Akt kinase inhibitors
JP6175076B2 (ja) 2012-01-20 2017-08-02 ボード オブ スーパーバイザーズ オブ ルイジアナ ステート ユニバーシティー アンド アグリカルチュラル アンド メカニカル カレッジ Ａｄ３６ｅ４ｏｒｆ１およびａｋｔ１阻害剤を使用した血糖コントロールの向上
GB201205164D0 (en) 2012-03-23 2012-05-09 Almac Discovery Ltd Pharmaceutical compounds
NO2868660T3 (es) 2012-07-02 2018-05-26
US9884067B2 (en) 2013-03-14 2018-02-06 University Of Maryland, Baltimore Androgen receptor down-regulating agents and uses thereof
KR20160104612A (ko) 2013-07-26 2016-09-05 업데이트 파마 인코포레이트 비산트렌의 치료 효과 개선용 조성물
US9808472B2 (en) 2013-08-12 2017-11-07 Tokai Pharmaceuticals, Inc. Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies
EP3718544A1 (en) 2013-10-01 2020-10-07 Novartis AG Combination
AU2014330780B2 (en) 2013-10-01 2017-05-25 Novartis Ag Enzalutamide in combination with Afuresertib for the treatment of cancer
WO2015094928A1 (en) * 2013-12-17 2015-06-25 Merck Sharp & Dohme Corp. Liposomal compositions for allosteric akt inhibitors
AU2015211021B2 (en) 2014-01-28 2020-07-02 Buck Institute For Research On Aging Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders
JP2017507963A (ja) 2014-03-12 2017-03-23 ノバルティス アーゲー Ｂｔｋ阻害薬とａｋｔ阻害薬を含む組み合わせ
US10022360B2 (en) * 2014-03-17 2018-07-17 Merck Sharp & Dohme Corp. Polymeric nanoparticles and methods of making and using same
CN107428779A (zh) 2015-02-27 2017-12-01 大鹏药品工业株式会社 咪唑并噁嗪晶体、含有所述晶体的药物组合物和制备所述晶体的方法
FR3033499A1 (fr) 2015-03-11 2016-09-16 Centre Leon-Berard Composition pour le traitement des tumeurs neuroendocrines pancreatiques
WO2017069275A1 (ja) * 2015-10-22 2017-04-27 田辺三菱製薬株式会社 新規二環性複素環化合物
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
WO2017156350A1 (en) 2016-03-09 2017-09-14 K-Gen, Inc. Methods of cancer treatment
CN108426971B (zh) * 2018-03-09 2020-03-20 浙江中一检测研究院股份有限公司 一种快速检测水中微囊藻毒素的方法
AU2021269065A1 (en) * 2020-05-08 2022-12-15 Georgiamune, Inc. Akt3 modulators and methods of use thereof
WO2024083716A1 (en) 2022-10-17 2024-04-25 Astrazeneca Ab Combinations of a serd for the treatment of cancer

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4361276B2 (ja) * 2001-04-10 2009-11-11 メルク エンド カムパニー インコーポレーテッド Ａｋｔ活性の阻害物質
CA2442264A1 (en) * 2001-04-10 2002-10-24 Merck & Co., Inc. A method of treating cancer
US20030187026A1 (en) * 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
JP4394961B2 (ja) * 2002-04-08 2010-01-06 メルク エンド カムパニー インコーポレーテッド Ａｋｔ活性の阻害剤としての融合キノキサリン誘導体
CA2480880C (en) * 2002-04-08 2011-03-22 Merck & Co., Inc. Inhibitors of akt activity
AU2003226250B2 (en) * 2002-04-08 2007-08-16 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
EP1496896A4 (en) * 2002-04-08 2007-10-31 Merck & Co Inc AKT INHIBITORS EFFECT
CA2501365C (en) * 2002-10-30 2011-05-31 Merck & Co., Inc. Inhibitors of akt activity
WO2004096130A2 (en) * 2003-04-24 2004-11-11 Merck & Co., Inc. Inhibitors of akt activity
CA2522262A1 (en) * 2003-04-24 2004-11-11 Merck & Co., Inc. Inhibitors of akt activity
DE602004023838D1 (de) * 2003-04-24 2009-12-10 Merck & Co Inc Hemmer der akt aktivität
AU2004233828B2 (en) * 2003-04-24 2009-05-28 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
WO2005007099A2 (en) 2003-07-10 2005-01-27 Imclone Systems Incorporated Pkb inhibitors as anti-tumor agents
CN1863779B (zh) * 2003-10-15 2010-05-05 宇部兴产株式会社 吲唑衍生物
JP2007008816A (ja) * 2003-10-15 2007-01-18 Ube Ind Ltd 新規イソキノリン誘導体
JP2007532551A (ja) 2004-04-09 2007-11-15 メルク　エンド　カムパニー　インコーポレーテッド Ａｋｔ活性の阻害剤
EP1737843B1 (en) * 2004-04-09 2011-02-23 Merck Sharp & Dohme Corp. Inhibitors of akt activity
US7544677B2 (en) * 2004-08-23 2009-06-09 Merck & Co., Inc. Inhibitors of Akt activity
CA2588474A1 (en) * 2004-12-02 2006-06-29 Merck & Co., Inc. Inhibitors of akt activity
CA2589084A1 (en) 2004-12-15 2006-06-22 Merck & Co., Inc. Inhibitors of akt activity
US7589068B2 (en) * 2005-02-14 2009-09-15 Merck & Co., Inc. Inhibitors of Akt activity
AU2006235314B2 (en) * 2005-04-12 2011-01-20 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
ES2409168T3 (es) 2005-06-10 2013-06-25 Merck Sharp & Dohme Corp. Inhibidores de la actividad Akt
MX2008009475A (es) * 2006-01-23 2008-10-20 Amira Pharmaceuticals Inc Inhibidores triciclicos de 5-lipoxigenasa.
AR064010A1 (es) * 2006-12-06 2009-03-04 Merck & Co Inc Inhibidores de la actividad de la akt
AU2008236670B2 (en) * 2007-04-05 2011-12-01 Amgen Inc. Aurora kinase modulators and method of use

Also Published As

Publication number Publication date
US20080161317A1 (en) 2008-07-03
CL2007003495A1 (es) 2008-05-30
KR20090086095A (ko) 2009-08-10
NO20092569L (no) 2009-07-06
PE20081341A1 (es) 2008-10-19
AU2007328286B2 (en) 2011-01-20
AU2007328286A2 (en) 2009-08-06
NZ577470A (en) 2011-11-25
BRPI0719580A2 (pt) 2013-12-17
NZ595829A (en) 2013-04-26
NI200900106A (es) 2010-01-20
JP5364454B2 (ja) 2013-12-11
WO2008070041A2 (en) 2008-06-12
EA016195B1 (ru) 2012-03-30
MX2009006052A (es) 2009-06-17
JP2009298786A (ja) 2009-12-24
JP2010511703A (ja) 2010-04-15
US7576209B2 (en) 2009-08-18
GEP20125469B (en) 2012-04-10
JP4431636B1 (ja) 2010-03-17
AU2007328286A1 (en) 2008-06-12
MA31027B1 (fr) 2009-12-01
CA2670760C (en) 2012-01-24
KR101110598B1 (ko) 2012-03-08
AR064010A1 (es) 2009-03-04
WO2008070041A3 (en) 2008-08-28
US20110160183A1 (en) 2011-06-30
WO2008070016A2 (en) 2008-06-12
US8288407B2 (en) 2012-10-16
EP2104669A2 (en) 2009-09-30
TN2009000224A1 (en) 2010-10-18
CN101600706B (zh) 2013-10-16
ECSP099376A (es) 2009-07-31
EA200970542A1 (ru) 2009-12-30
US20090253734A1 (en) 2009-10-08
HN2009001112A (es) 2011-07-22
IL198826A (en) 2010-11-30
HK1137758A1 (en) 2010-08-06
WO2008070016A3 (en) 2008-09-12
CA2670760A1 (en) 2008-06-12
CR10851A (es) 2009-06-25
IL205220A0 (en) 2011-07-31
CN101600706A (zh) 2009-12-09
EP2104669B1 (en) 2014-10-15
GT200900146A (es) 2010-04-13
SV2009003283A (es) 2009-11-09
TWI386410B (zh) 2013-02-21
TW200831509A (en) 2008-08-01
ES2527567T3 (es) 2015-01-26

Similar Documents

Publication Publication Date Title
CO6190528A2 (es) Inhibidores de la actividad de la akt
CO5261601A1 (es) Indolilquinolinonas utiles como inhibidores de la tirosinoquinasa
CO6190518A2 (es) Inhibidores de tirosina quinasa
CR20110001A (es) Compuesto heterocíclico y uso del mismo
PE20070189A1 (es) COMPUESTO DE AMINO-5-HETEROARILO (5 MIEMBROS) IMIDAZOLONA Y SU USO PARA MODULACION DE LA ß-SECRETASA
PE20140703A1 (es) Derivados de heteroarilo como moduladores de nachr alfa 7
ES2722548T3 (es) Compuestos de piracina para el tratamiento de enfermedades infecciosas
PE20091158A1 (es) 5-anilinoimidazopiridinas y metodos de uso
ES2531274T3 (es) Indazoles sustituidos con oxazol como inhibidores de PI3-cinasas
CR20120053A (es) Compuestos y metodos inhibidores de jak de pirazolopirimidina
ECSP099335A (es) Compuestos heterocíclicos que contienen nitrógeno y métodos de uso de los mismos
AR087591A1 (es) Derivados de ciclohexil azetidina como inhibidores de jak
AR052568A1 (es) Derivados de pirazolo -pirimidina como antagonstas de mglur2
AR064635A1 (es) Derivados de benzotiazolona
SV2009002865A (es) Uso de oxazolidinonas para el tratamiento y profilaxis de microangiopatias
AR084011A1 (es) Compuestos nitrogenados heterociclicos utiles para el tratamiento de infecciones por el virus sincitial respiratorio (rsv), proceso para prepararlos y composiciones farmaceuticas que los contienen
CL2010001415A1 (es) Compuestos derivados de diazacarbazol, con actividad inhibidora de quinasa; composición farmacéutica que comprende a uno de los compuestos; y uso de la composición farmacéutica en la preparación de medicamentos para la inhibición del crecimiento celular o el tratamiento de un trastorno hiperproliferativo
EA200971101A1 (ru) Соединения на основе лантибиотиков, обладающие противомикробной активностью
PE20130157A1 (es) Inhibidores de la polimerasa virica
PE20110196A1 (es) 5-alquinil-pirimidinas
AR066421A1 (es) Compuestos derivados de piridona
ECSP109958A (es) Derivados de pirimidina 934
AR077080A1 (es) Compuestos de 2,3-dihidro-1h-indeno
ECSP088805A (es) 2-(piridin-2-il)-pirimidinas como fungicidas
AR101964A1 (es) Compuestos de imidazopiridazina como moduladores de pi3k

Legal Events

Date Code Title Description
FG Application granted